Trabectedin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NICE (England) and PBAC (Australia) recommended or restricted trabectedin, while HIRA (South Korea) did not recommend it.
The file has been open for more than a decade: 15.6 years separate the first record, 2 Apr 2008 at HAS (France), from the most recent, 9 Nov 2023 at HIRA (South Korea).
SMC (Scotland) changed its position: not recommended on 13 Sep 2010, recommended by 9 Nov 2020, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
6 distinct indication wordings are recorded for trabectedin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 14 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess trabectedin, on 2 Apr 2008; HIRA (South Korea) did not open a file until 6 Jul 2023 — an unusually long tail of 15.2 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 10 years in total.
4 of the 6 agencies here assessed trabectedin more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for trabectedin.
The full ledger for trabectedin reads 7 recommended, 4 not recommended, 1 restricted and 1 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 9 Nov 2023 | 연조직 육종 | not reimbursed | source |
| PBAC (Australia) | 2021 | Advanced (unresectable and/or metastatic) leiomyosarcoma (LMS) | Recommended | source |
| SMC (Scotland) | 9 Nov 2020 | Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data … | accepted | source |
| HAS (France) | 16 May 2018 | Re-assessment of SMR and ASMR | SMR low · ASMR V | source |
| NICE (England) | 24 Feb 2010 | NICE TA185 | recommended (optimised) | source |
9 further decisions for trabectedin, across 4 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- docetaxel — same ATC class L01C — Antineoplastics
- paclitaxel — same ATC class L01C — Antineoplastics
- irinotecan — same ATC class L01C — Antineoplastics
- topotecan — same ATC class L01C — Antineoplastics
- cabazitaxel — same ATC class L01C — Antineoplastics
- vinorelbine — same ATC class L01C — Antineoplastics
Coverage: 14 decisions for trabectedin from 6 agencies, 2008 to 2023. Data to 7 Sep 2026. ATC class L01C — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.